

Resource Summary Report

Generated by NIF on Aug 1, 2026

Brilliant Violet 785(TM) anti-human CD279 (PD-1)

RRID:AB_2563443

Type: Antibody

Proper Citation

BioLegend Cat# 329930, RRID:AB_2563443

Antibody Information

URL: http://antibodyregistry.org/AB_2563443

Proper Citation: BioLegend Cat# 329930, RRID:AB_2563443

Target Antigen: CD279

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-human CD279 (PD-1)

Description: This monoclonal targets CD279

Target Organism: human

Clone ID: Clone EH12.2H7

Antibody ID: AB_2563443

Vendor: BioLegend

Catalog Number: 329930

Alternative Catalog Numbers: 329929

Record Creation Time: 20250820T051646+0000

Record Last Update: 20250820T211304+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-human CD279 (PD-1).

No alerts have been found for Brilliant Violet 785(TM) anti-human CD279 (PD-1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Fernandes P, et al. (2026) Functional immune responses induced by a capsid assembly modulator in chronic hepatitis B virus-infected humanized mice. *Cell host & microbe*, 34(1), 116.

Agarwal R, et al. (2025) Chikungunya virus-specific CD4+ T cells are associated with chronic chikungunya viral arthritic disease in humans. *Cell reports. Medicine*, 6(5), 102134.

Chauveau C, et al. (2025) MEK inhibition prevents human skin graft rejection by promoting CD8+TCF1+ over CD8 effector T cells. *iScience*, 28(9), 113310.

Schulenberg S, et al. (2025) Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trial. *iScience*, 28(11), 113680.

Kulkarni AJ, et al. (2025) L-Phenylalanine is a metabolic checkpoint of human Th2 cells. *Cell reports. Medicine*, 6(12), 102466.

Hirsch T, et al. (2024) IRF4 impedes human CD8 T cell function and promotes cell proliferation and PD-1 expression. *Cell reports*, 43(7), 114401.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. *Cell*, 187(26), 7470.

Faliti CE, et al. (2024) Interleukin-2-secreting T helper cells promote extra-follicular B cell maturation via intrinsic regulation of a B cell mTOR-AKT-Blimp-1 axis. *Immunity*, 57(12), 2772.

Mathews JA, et al. (2024) Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF- β 1 and IL-2 confer immunoregulatory functions to NK cells. *iScience*, 27(12), 111416.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. *Cell reports*, 44(1), 115102.

Darrah PA, et al. (2023) Airway T cells are a correlate of i.v. Bacille Calmette-Guerin-mediated protection against tuberculosis in rhesus macaques. *Cell host & microbe*, 31(6), 962.

Canale FP, et al. (2023) Proteomics of immune cells from liver tumors reveals immunotherapy targets. *Cell genomics*, 3(6), 100331.

Abhiraman GC, et al. (2023) A structural blueprint for interleukin-21 signal modulation. *Cell reports*, 42(6), 112657.

Zhang Z, et al. (2022) Humoral and cellular immune memory to four COVID-19 vaccines. *Cell*, 185(14), 2434.

Sudmeier LJ, et al. (2022) Distinct phenotypic states and spatial distribution of CD8+ T cell clonotypes in human brain metastases. *Cell reports. Medicine*, 3(5), 100620.

Hoang TN, et al. (2021) Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. *Cell*, 184(2), 460.

Rydyznski Moderbacher C, et al. (2020) Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell*, 183(4), 996.

Colomb F, et al. (2020) Sialyl-LewisX Glycoantigen Is Enriched on Cells with Persistent HIV Transcription during Therapy. *Cell reports*, 32(5), 107991.

Grifoni A, et al. (2020) Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*, 181(7), 1489.

Cirelli KM, et al. (2019) Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance. *Cell*, 177(5), 1153.